Latest news
Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) has accepted the first-ever Biol...
Warszawa, 18 lipca 2022 r. Polpharma Biologics, polska firma biotechnologiczna zajmująca się rozwojem i produkcją leków biologicznych ogłosiła, że Europejska Agencja Leków (European Medicines Agency – EMA) przyjęła wniosek (Marketing Authorization Application – MAA) o wydanie pozwolenia na dopuszczenie do obrotu na terenie Unii Europejskiej – leku biopodobnego zawierającego przeciwciało...
MHRA’s authorization for BIOEQ’s biosimilar in the United Kingdom.
We are pleased to share last week’s news on the approval of the marketing authorization application of BIOEQ’s Lucent...
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "we...
Zug, Switzerland – MS Pharma has signed an exclusive licensing and supply agreement with Bioeq AG, Switzerland, the P...
Bioeq has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application...
The new roles come on top of significant growth at the company in the last two years, with an additional 300 employee...
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has...
Our attention has been drawn to the fraudulent activities of persons posing as recruitment agencies or Polpharma Biol...